These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 12825462)

  • 21. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity.
    Williams PA; Cosme J; Sridhar V; Johnson EF; McRee DE
    Mol Cell; 2000 Jan; 5(1):121-31. PubMed ID: 10678174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites.
    Avent KM; DeVoss JJ; Gillam EM
    Chem Res Toxicol; 2006 Jul; 19(7):914-20. PubMed ID: 16841959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Filling a hole in cytochrome P450 BM3 improves substrate binding and catalytic efficiency.
    Huang WC; Westlake AC; Maréchal JD; Joyce MG; Moody PC; Roberts GC
    J Mol Biol; 2007 Oct; 373(3):633-51. PubMed ID: 17868686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bimolecular fluorescence complementation analysis of cytochrome p450 2c2, 2e1, and NADPH-cytochrome p450 reductase molecular interactions in living cells.
    Ozalp C; Szczesna-Skorupa E; Kemper B
    Drug Metab Dispos; 2005 Sep; 33(9):1382-90. PubMed ID: 15980100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In silico predictive metabolism: a structural/electronic filter method.
    Harris DL
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):43-8. PubMed ID: 14982147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. QSAR of cytochrome inhibitors.
    Roy K; Roy PP
    Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1245-66. PubMed ID: 19708826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Computational solvent mapping reveals the importance of local conformational changes for broad substrate specificity in mammalian cytochromes P450.
    Clodfelter KH; Waxman DJ; Vajda S
    Biochemistry; 2006 Aug; 45(31):9393-407. PubMed ID: 16878974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crystal structure of cytochrome P450 MoxA from Nonomuraea recticatena (CYP105).
    Yasutake Y; Imoto N; Fujii Y; Fujii T; Arisawa A; Tamura T
    Biochem Biophys Res Commun; 2007 Oct; 361(4):876-82. PubMed ID: 17679139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative structure-activity relationships (QSARs) within series of inhibitors for mammalian cytochromes P450 (CYPs).
    Lewis DF; Dickins M
    J Enzyme Inhib; 2001 Oct; 16(4):321-30. PubMed ID: 11916137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression, purification, and characterization of Bacillus subtilis cytochromes P450 CYP102A2 and CYP102A3: flavocytochrome homologues of P450 BM3 from Bacillus megaterium.
    Gustafsson MC; Roitel O; Marshall KR; Noble MA; Chapman SK; Pessegueiro A; Fulco AJ; Cheesman MR; von Wachenfeldt C; Munro AW
    Biochemistry; 2004 May; 43(18):5474-87. PubMed ID: 15122913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modeling of human cytochrome p450-mediated drug metabolism using unsupervised machine learning approach.
    Korolev D; Balakin KV; Nikolsky Y; Kirillov E; Ivanenkov YA; Savchuk NP; Ivashchenko AA; Nikolskaya T
    J Med Chem; 2003 Aug; 46(17):3631-43. PubMed ID: 12904067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications.
    Hollenberg PF; Kent UM; Bumpus NN
    Chem Res Toxicol; 2008 Jan; 21(1):189-205. PubMed ID: 18052110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Computer-assisted design of selective imidazole inhibitors for cytochrome p450 enzymes.
    Verras A; Kuntz ID; Ortiz de Montellano PR
    J Med Chem; 2004 Jul; 47(14):3572-9. PubMed ID: 15214784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Homotropic cooperativity of monomeric cytochrome P450 3A4 in a nanoscale native bilayer environment.
    Baas BJ; Denisov IG; Sligar SG
    Arch Biochem Biophys; 2004 Oct; 430(2):218-28. PubMed ID: 15369821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification.
    Iyanagi T
    Int Rev Cytol; 2007; 260():35-112. PubMed ID: 17482904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of membrane-contacting loops of the catalytic domain of cytochrome P450 2C2 by tryptophan fluorescence scanning.
    Ozalp C; Szczesna-Skorupa E; Kemper B
    Biochemistry; 2006 Apr; 45(14):4629-37. PubMed ID: 16584198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Crystal structure of inhibitor-bound P450BM-3 reveals open conformation of substrate access channel.
    Haines DC; Chen B; Tomchick DR; Bondlela M; Hegde A; Machius M; Peterson JA
    Biochemistry; 2008 Mar; 47(12):3662-70. PubMed ID: 18298086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein dynamics and imidazole binding in cytochrome P450 enzymes.
    Verras A; Ortiz de Montellano PR
    Biochem Soc Trans; 2006 Dec; 34(Pt 6):1170-2. PubMed ID: 17073778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The structure of microsomal cytochrome P450 2C5: a steroid and drug metabolizing enzyme.
    Johnson EF; Wester MR; Stout CD
    Endocr Res; 2002 Nov; 28(4):435-41. PubMed ID: 12530646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.